Boston, MA 10/17/2013 (wallstreetpr) – In a span of 30 day in the month of September, Geron Corporation (NASDAQ:GERN) managed to get its market value up by 76%. However, in the past week GERN has caved in 14% in its market cap. But this trouble was expected following the human embryo stem cell announcement on October 1. It therefore means that this slip in market value is just an incident.
Principally, things are looking up for this a biopharmaceutical company who market as at Wednesday, October 16, stood at $538.40 million. For the past 12 months, GERN has witnessed a sales turnover in the region of $2.2 million and a net loss of $52 million. This company has its place at above $4 per share. And the investors who purchased the stock six months ago are looking at the possibilities of their investment attracting around 151% value-gain.
With GERN still climbing, it is not late to still get a piece of this stock that is aggressively setting its new highs and lows limits rather faster than its peers.
The rally at GERN was not escaped the attention of equities analysts. At least five research analysts have so far echoed their sentiments on the stock, giving it a consensus “hold” and a price target of $4.08.
Rating agencies like MLV Capital are more bullish on the stock assign “buy” at price objective of $6.50. At this price target, it means investors are looking at a share value upside of 108.33% on the stock.
In the most recent earnings results, GERN reported $0.07 EPS on $0.11 million revenue. While this EPS was inline with Thomson Reuters’ estimate ($0.07), the quarter’s revenue missed the consensus estimate of $0.50 by a wide margin. But the problems of then have been addressed and in the next six months, company is taking its investors somewhere.
GERN is a biopharmaceutical company involved in development of cancer therapies.
